siga technologies inc
(SIGA:NASDAQ SE Consolidated Large Cap)
siga technologies inc (SIGA) Snapshot
|
Open
$3.59
|
Previous Close
$3.60
|
|
|
Day High
$3.71
|
Day Low
$3.53
|
|
|
52 Week High
03/11/13 - $4.60
|
52 Week Low
05/31/12 - $2.20
|
|
|
Market Cap
190.8M
|
Average Volume 10 Days
144.8K
|
|
|
EPS TTM
$-0.29
|
Shares Outstanding
52.1M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
siga technologies inc (SIGA) Related Businessweek News
No Related Businessweek News Foundsiga technologies inc (SIGA) Details
SIGA Technologies, Inc., a pharmaceutical company, engages in the development and commercialization of pharmaceutical solutions for smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. The company’s lead product is Arestvyr, an orally administered antiviral drug that targets orthopoxviruses. It also has various drug series in the pre-clinical development stage against four serotypes of virus for dengue disease. In addition, the company develops anti-arenavirus drug for hemorrhagic fever arenaviruses comprising Lassa virus and sabia virus; other hemorrhagic fever viruses, including Rift Valley Fever, Lymphocytic choriomeningitis virus, and Ebola; and a broad spectrum antiviral candidate against viruses in the Poxviridae, Filoviridae, Bunyaviridae, Arenaviridae, Flaviviridae, Togaviridae, Retroviridae, and Picornaviridae families. SIGA Technologies, Inc. was founded in 1995 and is headquartered in New York, New York.
siga technologies inc (SIGA) Top Compensated Officers
siga technologies inc (SIGA) Key Developments
SIGA Technologies, Inc. announced earnings results for the first quarter ended March 31, 2013. Revenue for the three months ended March 31, 2013 was $1.3 million, compared to $1.5 million in the first quarter of 2012, and the operating loss for the quarter was $5.8 million, compared to $5.5 million for the comparable quarter last year. Revenues decreased mainly due to a decrease in revenues from the federal contracts supporting the development of Arestvyr(TM).
On 05/13/2013, SIGA Technologies, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
SIGA Technologies, Inc., Q1 2013 Earnings Call, May 06, 2013
| Recently Viewed | |||
| SIGA:US | $3.66 USD | +0.06 |  |
| Company | Last | Change |
| Bavarian Nordic A/S | kr67.00 DKK | 0.00 |
| Chimerix Inc | $21.81 USD | +1.07 |
| Emergent Biosolutions Inc | $14.16 USD | -0.10 |
| GlaxoSmithKline PLC | 1,750 GBp | +7.50 |
| View Industry Companies | ||
Industry Analysis
SIGA
Industry Average
| Valuation | SIGA | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 21.1x |
|
| Price/Book | 7.4x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 17.9x |
|
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact SIGA TECHNOLOGIES INC, please visit www.siga.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
